Pfisterer, Jacobus <br/><br/>
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Oct 2006 
 - 4699-707 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2006.06.0913  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--pharmacology<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Carboplatin--administration & dosage<br/>Cisplatin--pharmacology<br/>Deoxycytidine--administration & dosage<br/>Disease Progression<br/>Female<br/>Humans<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Ovarian Neoplasms--drug therapy<br/>Quality of Life<br/>Survival Analysis<br/>Treatment Outcome<br/>Gemcitabine